CA
MRNA icon

Centerpoint Advisors’s Moderna MRNA Stock Holding History

Centerpoint Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-274
Closed -$29K – 461
2024
Q1 		$29K Hold
274
– – 0.01% 208
2023
Q4 		$27K Hold
274
– – 0.01% 197
2023
Q3 		$28K Hold
274
– – 0.01% 194
2023
Q2 		$33K Hold
274
– – 0.01% 194
2023
Q1 		$42K Hold
274
– – 0.02% 178
2022
Q4 		$49K Buy
+274
New +$44.8K 0.02% 142

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Centerpoint Advisors's MRNA Position: Q2 2024 in Review

Centerpoint Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 274 shares — an estimated $29K sold.

Centerpoint Advisors first reported a position in MRNA in Q4 2022 and held it in 6 quarters. The position peaked at $49K in Q4 2022. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Centerpoint Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Centerpoint Advisors sold 274 Moderna shares in Q2 2024, an estimated $29K.
  • Centerpoint Advisors first reported a position in Moderna in Q4 2022 and held it in 6 quarters.
  • Centerpoint Advisors's Moderna position peaked at $49K in Q4 2022.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Centerpoint Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.